Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP finds

2 years ago 34
ARTICLE AD BOX
U.S. health inspectors are still struggling to address a massive backlog of pharmaceutical plants that went uninspected during disruptions caused by COVID-19
Read Entire Article